Figures & data
Figure 1. Characteristics of circTXNDC11 in RCC
(a) Schematic illustration of circTXNDC11. (b, c) qRT-PCR for the relative expression of circTXNDC11 and TXNDC11 in RCC cells treated with RNase R and Actinomycin D. (d) The cellular location of circTXNDC11 in RCC cells; *P < 0.05.
Figure 2. Relative expression of circTXNDC11 in RCC
(a, b) circTXNDC11 expression in GSE100186 (a) and GSE137836 (b) datasets. (C, D) qRT-PCR detected the expression of circTXNDC11 in RCC tissues (c) and cell lines (d). (e, f) High circTXNDC11 expression was associated with advanced TNM stage (e) and lymph-node metastasis (f) in RCC; *P < 0.05.
Figure 3. circTXNDC11 knockdown inhibited the proliferation and invasion of RCC cells in vitro
(a) qRT-PCR for the transfection efficacy of si-circTXNDC11 in RCC cells. (B–F) Effect of circTXNDC11 knockdown on proliferation (b) colony formation (c), apoptosis rate (d), and metastasis (e, f) of RCC cells in vitro; *P < 0.05.
Figure 4. circTXNDC11 silencing reduced RCC cell growth in vivo
(a) Transfection efficacy of sh-circTXNDC11 in 786-O cells. (b) circTXNDC11 suppression reduced the growth of RCC tumor in nude mice. (c, d) circTXNDC11 inhibition decreased the volume and weight of xenograft tumors in nude mice; *P < 0.05.
Figure 5. GO and KEEG pathway analysis of circTXNDC11 in RCC
(a–c) The top 10 processes of circTXNDC11 enrichment in biological process (BP), molecular functions (MF), and cellular component (CC), respectively, by GO analysis. (d) The top 30 pathways of circTXNDC11 enrichment predicted by KEEG analysis.
Figure 6. circTXNDC11 activated the MAPK/ERK pathway in RCC
(a, b) The effects of si-circTXNDC11 on the expression of p-ERK, ERK, p-MEK, and MEK proteins in 786-O cells. (c–f) ERK inhibitor (SCH772984) abolished the biological effects of circTXNDC11 overexpression in 786-O cell proliferation (c, d) and invasion (e, f); *P < 0.05.
